Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult

CHAIR: Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX

View Webcast Now

AGENDA TOPICS:

• Utilize risk stratification strategies to develop appropriate treatment plans for  patients with ALL
• Assess the importance of minimal residual disease and its role in determining prognosis as well as in treatment planning
• Review the safety and efficacy of emerging therapies in the management of ALL

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen, Jazz Pharmaceuticals, Servier Pharmaceuticals LLC, and Takeda Oncology.